Page 1
For peer review only
Do US Thyroid Cancer Incidence Rates Increase with
Socioeconomic Status among People with Health Insurance?
Journal: BMJ Open
Manuscript ID: bmjopen-2015-009843
Article Type: Research
Date Submitted by the Author: 31-Aug-2015
Complete List of Authors: Altekruse, Sean; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences Das, Anita; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences Cho, Hyunsoon; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences; National Cancer Center, Division of Cancer Registration and Surveillance Petkov, Valentina; National Cancer Institute, Surveillance Research
Program, Division of Cancer Control and Population Sciences Yu, Mandi; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences
<b>Primary Subject Heading</b>:
Oncology
Secondary Subject Heading: Epidemiology
Keywords: Endocrine tumours < ONCOLOGY, Epidemiology < ONCOLOGY, PUBLIC HEALTH
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open on A
pril 25, 2022 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2015-009843 on 7 Decem
ber 2015. Dow
nloaded from
Page 2
For peer review only
1
Do US Thyroid Cancer Incidence Rates Increase with Socioeconomic Status among People with Health
Insurance?
Sean Altekruse1, Anita Das1, Hyunsoon Cho1,2, Valentina Petkov1, Mandi Yu1
1. National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences
Rockville, Maryland, United States
2. National Cancer Center, Division of Cancer Registration and Surveillance
Goyang, Korea (the Republic of)
Abstract: 238 words
Text: 2 259 words
Tables: 3
Figures: 1
References: 34
Key words: Thyroid cancer; Incidence; Insurance; Socioeconomic Status; Overdiagnosis
Running header: Thyroid cancer, socioeconomic, and insurance status
Correspondence to: Sean F. Altekruse, Surveillance Research Program, Division of Cancer Control and Population
Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive 4E536, Rockville MD
20850
Telephone: 240.276.6933
Fax: 240.276.7908
E-mail: [email protected]
Page 1 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 3
For peer review only
2
Abstract
Objectives: To determine the extent to which access to health care and census tract socioeconomic status influence
incidence of thyroid cancer, and particularly papillary thyroid cancer (PTC).
Design: Relationships between thyroid cancer incidence, insurance and census-tract socioeconomic status (SES)
during 2007-2010 were examined in population-based cancer registries. Cases were stratified by tumor histology,
size and demography.
Setting: Surveillance, Epidemiology, and End Results (SEER) registries covering 25% of the US population.
Results: PTCs accounted for 88% of incident thyroid cancer cases. Small PTCs (≤2 cm) accounted for 60% of
cases. Unlike non-PTC cases the majority of those diagnosed with PTC were <50 years of age and had ≤2 cm
tumors. Rate ratios (RR) of PTC diagnoses increased monotonically with SES among fully insured cases. The effect
was strongest for small PTCs, high- versus low-SES quintile RR=2.7, 95% confidence interval (CI): 2.6–2.9, two-
sided trend test P < 0.0001. For small PTC cases with insurance the monotonic increase in incidence rates with
rising SES persisted among cases younger than 50 years of age (RR=3.3, 95% CI=3.0–3.5), women (RR=2.6, 95%
CI=2.5–2.8) and whites (RR=2.5, 95% CI=2.4–2.7). Among other than fully insured cases, RRs were typically less
than one in high versus the lowest SES strata.
Conclusion: The greater than 2.5 fold increase in risk of PTC diagnosis among insured individuals associated with
high SES may be informative with respect to the contemporary issue of papillary thyroid cancer overdiagnosis.
Strengths and limitations of this study
• The study included 41 072 incident thyroid cancer case during 2007-2010 across 25% of the US population.
• Rate ratios and confidence intervals were used to assess effects of SES and insurance on thyroid cancer incidence.
• Effects were also examined by patient attributes, tumor size, and histology.
• Potential misclassification of histology data from population-based pathology reports was a limitation of this study.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing Interests
The authors have no conflicts of interest to declare.
Page 2 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 4
For peer review only
3
Introduction
In Surveillance, Epidemiology, and End Results (SEER) registry data for the United States from 1975–2011,
thyroid cancer incidence rates tripled (1-3) while US thyroid cancer mortality trends were steady (1). These
discrepant trends are consistent with cancer overdiagnosis (2-4). Similar patterns are reported in many but not all
industrialized countries (3). Thyroid cancer incidence rates are higher among women than men (5) and among
whites than other major racial groups (6,7). Most of the rising incidence results from the increasing diagnosis of
small papillary thyroid cancers (PTCs) (2-4,8-10).
Access to health insurance contributes to the overdiagnosis of small PTCs (3,11-13) which carry relatively low
risk of death (3). Incidence rates of small PTCs are elevated in high-socioeconomic status (SES) counties (7,14,15)
and census tracts (11,12). Overdiagnosis and overtreatment of PTCs are associated with adverse effects, including
postsurgical complications, extended hospitalization, and lifelong hormone replacement therapy (2-4,16). In
contrast, several non-PTC types, including follicular, medullary, and anaplastic thyroid cancers carry progressively
worse prognoses (17). The present analysis, based on population-level cancer registry data covering approximately
25% of the United States, demonstrates the magnitude of combined effects of neighborhood socioeconomic status,
or SES (18, 19), and personal insurance status on the overdiagnosis of small PTCs including by age, gender, race
and ethnicity.
Materials and Methods
Data were obtained from 16 National Cancer Institute (NCI) SEER registries that cover approximately one-
quarter of the US population. The SEER November 2012 dataset was used for all analyses. Registries included in
analyses were Connecticut, Detroit, Hawaii, San Francisco-Oakland, Atlanta, Iowa, New Mexico, Seattle-Puget
Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, Greater California, Greater Georgia, Kentucky, and
New Jersey. Alaska Native cases were excluded because census-tract attributes were not available, and Louisiana
cases were excluded because of uncertainty about the population impact of Hurricane Katrina on census tract SES.
Case Attributes
Gender and age distributions (<50 years, 50–64 years, and ≥65 years of age at diagnosis) were examined. Race
and ethnicity were defined as Hispanic, non-Hispanic white, non-Hispanic black, and non-Hispanic Asian/Pacific
Page 3 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 5
For peer review only
4
Islander. Non-Hispanic American Indian/Alaska Natives and other and unknown race were combined as one group.
Tumors were classified as ≤2cm, >2cm, and unknown size. When ≤10 cases were observed data were suppressed.
Histologic Classification
Only malignant primary thyroid cancers were included in analyses. Thyroid cancer histologic classifications
were coded using the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) (20). A total of
283 cases with poorly specified cancer histologies (ICD-O-3 morphologies 8000–8005) were excluded. ICD-O-3
histology codes for papillary thyroid cancer were 8050,8052,8260,8340,8341,8342,8343,8344. , Other types were
follicular (8290,8330,8331,8332,8335), medullary (8290,8330,8331,8332,8335) and anaplastic thyroid cancer
(8012,8020-8021,8030-8032). Approximately 2% of cases were diagnosed with non-classical thyroid cancer
histologies including 284 cases (1%) with other epithelial neoplasms (8010,8013,8015,8022,8033,8035,8041,8046)
and 377 cases (1%) with other rare specified primary thyroid cancer histologies (8070-8072,8074,8082-
8083,8130,8140-8141,8190,8200-8201,8230,8240,8246,8255,8262-8263,8310,8323,8337,8347,8350,8430,8450,
8452,8460,8480-8481,8504,8507,8560,8570,8588-8589,8800,8802,8810,8830,8890,8980,9040-9041,9071,9080,
9120,9250,9364). These included adenocarcinomas and squamous cell carcinoma, which are referenced on the
SEER thyroid/histology validation list (21) and other specified histologies that are not found in the SEER validation
list but were abstracted from patients’ medical records.
Insurance
SEER data include the six category variable “Insurance Recode” for diagnosis year 2007 forward, derived from
the more detailed “Primary Payer at Diagnosis” variable. For the purpose of the present analysis, categories were
collapsed into “Fully Insured,” and “Other than Fully Insured.” “Fully Insured” is defined by the following seven
categories of health insurance: 1. Insured - Private Insurance: Fee-for-Service, 2. Private Insurance: Managed care,
3. HMO or PPO, 4. TRICARE, 5. Medicare - Administered through a Managed Care plan, 6. Medicare with private
supplement, 7. Medicare with supplement, NOS and 7. Military. “Other than Fully Insured,” included 1. Uninsured
cases; 2. Cases with Medicaid, Indian Health Service insurance and 3. Patients reported to be insured without further
information available. The 1,228 cases with missing data on insurance status were excluded from insurance-related
analysis.
Page 4 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 6
For peer review only
5
Census-Tract Level SES
SES is typically measured using county-level attributes as a proxy for individual data. However, county-level
SES attributes are less precise than smaller-area or individual SES attributes. To improve area-based SES estimates,
we used a year-dependent census-tract SES composite index (18) linked to SEER cases by the census tracts of
residence at time of diagnosis. The SES index was generated from seven variables (percent working class
population, percent adult unemployment, educational attainment, median household income, percent of population
living below 150% of national poverty line, median rent, and median home value) capturing three principal
components of SES (income, occupation, education) based on factor analysis (18). The output factor that explains
more than 90% of common variance among these variables is called the “SES index.” This index was constructed
separately for 2007, 2008, 2009, and 2010 using the 5-year estimates from the 2005–2009, 2006–2010, 2007–2011,
and 2008–2012 American Community Surveys, respectively. Census tracts were categorized into SES quintiles
according to this index, with equal populations in each quintile. The first quintile (Q1, lowest SES) is the 20th
percentile or less, and the fifth quintile (Q5, highest SES) corresponds to the 80th percentile or higher. The SES
index used in the present study has the advantage over specific area level SES measures of protecting against
disclosure of case identity through identification of a census tract with a unique permutation of multiple SES
attributes. The index is linked to the SEER data and is available for public use upon request from the authors. A total
of 642 cases were missing data on SES and were excluded from SES-related analysis.
Incidence by Insurance and SES
Age-adjusted incidence rates (22) were calculated by tumor size, insurance status, SES, and histology for cases
diagnosed during 2007–2010, years during which insurance data were available (SEER*Stat version 8.1.5, IMS,
Inc., Calverton, MD). Thyroid cancer incidence rates per 100 000 persons were directly age-adjusted to the 2000 US
population. Rate ratios (RR) and 95% confidence intervals (CIs) were calculated using the SES lowest quintile as
the reference. Regression models were used to estimate the percentage change in rate by SES (23) for PTC and non-
PTC histologies using the SAS PROC REG procedure (SAS 9.3, Cary, NC). The regression line slope was
considered to statistically differ from zero at a cutoff of p ≤ 0.05 based on a two-sided test.
Page 5 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 7
For peer review only
6
Results
Demographics
Characteristics of patients diagnosed with specified thyroid cancer types during 2007–2010 are summarized in
Table 1. The 41 072 cases were diagnosed with the following thyroid cancer types: 36 020 papillary (88%), 3 288
follicular (8%), 722 medullary (2%), 381 anaplastic (1%), 284 other epithelial (1%), and 377 other histologies (1%).
Half of cases (49%) were less than 50 years of age, including 51% of PTC cases. Most cases in other histologic
groups were 50 years of age or older. Women accounted for 76% of all cases, including 77% of all PTC cases.
Compared to the overall proportion of Asian/Pacific Islander thyroid cancer cases, this racial group accounted for a
high proportion of anaplastic tumors (13%), while blacks accounted for a high proportion of follicular, medullary
(9% each), and other epithelial tumors (10%). Among whites and Hispanics, tumor type distributions were more
similar to overall thyroid cancer case distributions. Most PTCs (69%) were ≤2 cm (small PTCs). Small PTCs
accounted for 24 745 of all 41 072 thyroid cancer cases (60%). Most follicular thyroid (69%) and anaplastic thyroid
cancer (76%) tumors were >2cm in size. PTC cases had the highest percentage of full insurance coverage (74%).
The percentage of full insurance coverage ranged from 60% for cases with anaplastic and other epithelial tumors to
72% for follicular tumors. Overall, 3% of cases had missing insurance data. The analysis of SES was restricted to 40
430 cases because of missing census tract data for 642 cases. The number of cases increased with SES for each type
of thyroid cancer, more than doubling for PTC—from quintile 1 to 5—and increased by 60% for follicular cancer,
31% for medullary, 49% for anaplastic, 29% for other epithelial, and 67% for other specified cancers.
Insurance and SES
Among fully insured cases RRs for PTC incidence increased monotonically with SES (Table 2). The RR in the
high compared to the low SES stratum was 2.6 (95% CI: 2.4–2.7), two-sided trend test of rate, P < 0.0001. For small
PTCs this RR reached 2.7 (95% CI: 2.6–2.9), two-sided trend test P < 0.0001. This monotonic effect persisted
among patients with small PTCs including females and whites (Table 3). The effect appeared to strengthen among
individuals younger than 50 years, with an RR in the high compared to the low SES stratum of 3.3 (95% CI: 3.0–
3.5), two-sided trend test of rate, P < 0.0003. Elevated RRs associated with high SES and insurance were also seen
among men and Asians (Figure 1). Among insured non-PTC cases RRs did not increase monotonically with SES.
Among other than fully insured, RRs were typically less than one in high SES strata compared to the referent group.
Page 6 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 8
For peer review only
7
Discussion
In this SEER study among fully insured cases, risk of PTC diagnosis increased monotonically with SES. This
association was driven diagnosis of small PTCs, with a 2.7-fold higher rate in the highest compared to the lowest
SES quintile. The effect persisted within several subgroups including persons less than 50 years of age, women, and
whites. These overlapping subgroups comprise a large proportion of all cases, with large numbers of subjects in each
SES stratum. Among the “other than fully insured,” a more heterogeneous group including Medicaid and uninsured
patients, thyroid cancer incidence did not increase with SES. The enumeration of risk among insured cases in high
SES compared to low SES areas may inform current discussions pertaining to PTC overdiagnosis.
The present study is a large SEER population-based study, covering a quarter of the population, with both
census-tract SES and individual insurance data. The results are more detailed than previous studies of thyroid cancer
incidence and SES (3,7,11-15,24) or health insurance coverage (12-15) with findings that differ from early studies
that found no association with SES or insurance (25,26). Our study and an earlier New Jersey study spanning 1979–
2006 (12) include census tract-level SES. The New Jersey study included county-level insurance data, while the
present study is based on individual-level insurance data. This is the first report of which we are aware to report a
monotonic increase in PTC incidence rates with rising SES among insured cases. Our findings indicate that this
effect is largely driven by small PTCs.
The rising incidence of small PTCs is described as an epidemic of diagnosis (2-4), disproportionately affecting
women (4,5,11,12) and patients under 50 years of age (5). Although small PTCs accounted for 60% of thyroid
cancer cases in this report, previous studies indicate PTCs account for less than 5% of thyroid cancer deaths and that
other thyroid cancer types carry far worse prognoses (17). The higher incidence of PTC among insured individuals
residing in high SES areas could be a consequence of higher paid individuals being “overinsured” relative to lower
paid “underinsured” workers (27). Overinsurance could increase access to imaging and biopsy for cancer screening
and evaluation of benign thyroid conditions. Such technologies may detect small, relatively low-risk thyroid nodules
(2,4). In one study, areas with high numbers of young physicians reported increased incidence rates of thyroid
cancer compared to areas with high concentrations of older physicians (28). The authors postulated that there is
greater use of ultrasound-guided biopsy by young physicians trained in these technologies. If these diagnostic
Page 7 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 9
For peer review only
8
resources are more likely to be found in high SES areas, it could contribute to associations between affluence and
PTC incidence.
Unless needed, post-diagnosis thyroidectomy and radiation place patients with small PTCs at risk for avoidable
surgical complications, lifetime thyroid replacement therapy, and perhaps second malignancies (2-4). The cost of
care for US patients diagnosed with well-differentiated thyroid cancer exceeded $1.6 billion in 2013 alone, including
more than $0.5 billion each for initial treatment and continued follow-up (29). American Thyroid Association
(ATA) Management guidelines (30) for patients with thyroid nodules encourage non-invasive management unless
patients have risk factors such as a family history of thyroid cancer, specific medical or environmental radiation
exposures, or rapid tumor growth with hoarseness. One recent study estimated that, in the United States,
approximately 82 000 men and women were diagnosed with papillary thyroid cancers during 1981-2011 that would
never cause symptoms (31). It has been proposed that some small PTCs be reclassified as non-cancers (2,3,10) or
that the most biologically indolent tumors be managed with watchful waiting (2-4). Reclassifying any PTCs as non-
cancerous would affect cancer survival statistics (32), because thyroid cancer survival is known to vary by stage,
age, gender and treatment (33). Biomarker research may also help to distinguish thyroid cancers including PTCs that
are likely to exhibit aggressive behavior from other, more indolent types (34).
Strengths of this study include availability of SEER variables for census-tract SES and individual insurance
status in registries covering 25% of the US population. Most studies of thyroid cancer incidence and SES (3,7,11,13-
15,24) have measured SES at the county or registry level. Study limitations include potential misclassification of
histology and availability of insurance data only for 4 recent years. In summary, compared to persons with insurance
living in low SES areas, those from high SES areas had more than 2.5 fold higher risk of being diagnosed with PTC.
The association was driven by small PTCs and persisted among persons younger than 50 years, women and whites.
Quantifying the risk of PTC associated with SES and insurance may inform efforts to prevent overdiagnosis.
Data Sharing
The SES index used in this report is linked to the SEER public research dataset and is available from the authors
upon review of request.
Page 8 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 10
For peer review only
9
References
1. NCI. SEER Cancer Statistics Review, 1975–2011. http://seer.cancer.gov/csr/1975_2011/. Accessed October 7,
2014.
2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg.
2014;140(4):317–322.
3. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of
low risk tumours. BMJ. 2013;347:4706.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA.
2006;295(18):2164–2167.
5. Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the
thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092–1100.
6. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United
States by histologic type, 1992-2006. Thyroid. 2011;21(2):125–134.
7. Morris LG, Sikora AG, Myssiorek D, DeLacure MD. The basis of racial differences in the incidence of thyroid
cancer. Ann Surg Oncol. 2008;15(4):1169–1176.
8. Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am.
2012;96(2):369–383.
9. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated
thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357–1361.
10. How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ.
2007;177(11):1383–1384.
11. Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer
in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11(12):163–170.
12. Roche LM, Niu X, Pawlish KS, Henry KA. Thyroid cancer incidence in New Jersey: time trend, birth cohort
and socioeconomic status analysis (1979-2006). J Environ Public Health. 2011;2011:850105.
13. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of
access to care. Thyroid. 2013;23(7):885–891.
Page 9 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 11
For peer review only
10
14. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer
incidence in the United States: review of incidence trends by socioeconomic status within the Surveillance,
Epidemiology, and End Results registry, 1980-2008. Thyroid. 2013;23(1):103–110.
15. Sprague BL, Warren Andersen S, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of
health care access. Cancer Causes Control. 2008;19(6):585–593.
16. Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am.
1989;18(2):359–387
17. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP. Thyroid cancer incidence and survival in the National
Cancer Institute Surveillance, Epidemiology, and End Results race/ethnicity groups. Thyroid. 2010;20(5):465–473.
18. Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate
health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014;25(1):81–
92.
19. Yost K, Perkins C, Cohen R, Morris C, Wright W.Socioeconomic status and breast cancer incidence in
California for different race/ethnic groups. Cancer Causes Control. 2001 Oct;12(8):703-11.
20. Percy C, Fritz A, Jack A, et al, eds. International classification of diseases for oncology (ICD-O). 3rd ed.
Geneva, Switzerland: World Health Organization; 2000.
21. NCI. ICD-O-3 SEER Site/Histology Validation List http://seer.cancer.gov/icd-o-3/. Accessed June 30, 2015
22. National Cancer Institute. Standard Populations (Millions) for Age-Adjustment Website; 2013.
http://seer.cancer.gov/stdpopulations/. Accessed October 7, 2014.
23. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort
studies. IARC Sci Publ. 1987;(82):1–406.
24. Hall SF, Irish J, Groome P, Griffiths R. Access, excess, and overdiagnosis: the case for thyroid cancer. Cancer
Med. 2014;3(1):154–161.
25. Haselkorn T, Stewart SL, Horn-Ross PL. Why are thyroid cancer rates so high in Southeast Asian women living
in the United States? The Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev. 2003;12(2):144–150.
26. Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW. An epidemiologic study of thyroid cancer in
Hawaii. Cancer Causes Control. 1990;1(3):223–234.
Page 10 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 12
For peer review only
11
27. Robertson CT. Scaling cost-sharing to wages: how employers can reduce health spending and provide greater
economic security. Yale J Health Policy Law Ethics. 2014;14(2):239-95.
28. Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH. Age of diagnosing physician impacts the
incidence of thyroid cancer in a population. Cancer Causes Control. 2014; 25(12):1627–1634.
29. Lubitz CC, Kong CY, McMahon PM, et al. Annual financial impact of well-differentiated thyroid cancer care in
the United States. Cancer. 2014;120(9):1345–1352.
30. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
31. O’Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the united states
1981-2011. Int J Cancer. 2015 Jun 9. doi: 10.1002/ijc.29634. [Epub ahead of print]
32. Ho AS, Davies L, Nixon IJ, et al. Cancer. Increasing diagnosis of subclinical thyroid cancers leads to spurious
improvements in survival rates. 2015 Jun 1;121(11):1793-9.
33. Banerjee M, Muenz DG, Worden F, Wong SL, Haymart MR. Conditional survival in thyroid cancer patients
[published online ahead of print October 8, 2014]. Thyroid. 2014; 24(12):1784–1789.
34. Baldini E, Sorrenti S, Tuccilli C, et al. Emerging molecular markers for the prognosis of differentiated thyroid
cancer patients. Int J Surg. 2014;12(suppl 1):S52–S56.
Page 11 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 13
For peer review only
12
Figure Legend
Figure 1. Thyroid cancer rate ratios by SES and insurance status for papillary and other histologies stratified by
tumor size, age, race, and gender -- SEER registries, 2007-2010*
*SEER 18 excluding Louisiana and Alaska cases and 283 additional cases with poorly specified histologies (ICD-O-
3 morphologies 8000–8005).
Author's contributions
Sean Altekruse: Design; acquisition, analysis, and interpretation of data. Drafting and revising for important
intellectual content. Final approval of the version to be published; and agreement to be accountable for the accuracy
and integrity of any part of the work.
Anita Das: Design; acquisition and interpretation of data. Final approval of the version to be published; and
agreement to be accountable for the accuracy and integrity of any part of the work.
Hyunsoon Cho: Design; analysis, and interpretation of data. Drafting and revising of content. Final approval of the
version to be published; and agreement to be accountable for the accuracy and integrity of any part of the work.
Valentina Petkov: Analysis, and interpretation of data. Drafting and revising of content. Final approval of the
version to be published; and agreement to be accountable for the accuracy and integrity of any part of the work.
Mandi Yu: Design, acquisition, analysis, and interpretation of data. Drafting and revising for important intellectual
content. Final approval of the version to be published; and agreement to be accountable for the accuracy and
integrity of any part of the work.
Page 12 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 14
For peer review only
13
Table 1. Characteristics of thyroid cancer cases by histologic group, SEER registries 2007–2010*
Histology groups
Papillary Follicular Medullary Anaplastic Other
epithelial
Other
specified
Total
No. % No. % No. % No. % No. % No. % No. %
Diagnosis age
<50 years 18 358 51% 1 333 41% 279 39% 20 5% 65 23% 136 36% 20 191 49%
50–64 years 11 603 32% 1 026 31% 238 33% 90 24% 67 24% 117 31% 13 141 32%
65+ years 6 059 17% 929 28% 205 28% 271 71% 152 54% 124 33% 7 740 19%
Sex
Female 27 906 77% 2 304 70% 445 62% 233 61% 186 65% 257 68% 31 331 76%
Male 8 114 23% 984 30% 277 38% 148 39% 98 35% 120 32% 9 741 24%
Race/ethnicity†
White† 24 285 67% 2 241 68% 494 68% 264 69% 182 64% 251 67% 27 717 67%
Page 13 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 15
For peer review only
14
Hispanic 5 540 15% 412 13% 108 15% 45 12% 34 12% 47 12% 6 186 15%
API† 3 684 10% 264 8% 35 5% 51 13% 32 11% 34 9% 4 100 10%
Black† 1 930 5% 312 9% 68 9% 18 5% 28 10% 34 9% 2 390 6%
Other 581 2% 59 2% 17 2% * * * * 11 3% 679 2%
Tumor size (cm)
≤2cm 24 745 69% 784 24% 347 48% * * * * 154 41% 26 083 64%
>2cm 9 907 28% 2 271 69% 326 45% 289 76% 106 37% 172 46% 13 071 32%
Unknown 1 368 4% 233 7% 49 7% 83 22% 134 47% 51 14% 1 918 5%
Insurance status
Fully insured 26 800 74% 2 366 72% 497 69% 227 60% 169 60% 265 70% 30 324 74%
Uninsured 847 2% 83 3% 27 4% * * * * * * 985 2%
Any Medicaid 2 621 7% 289 9% 80 11% 47 12% 40 14% 35 9% 3 112 8%
Insured, NOS 4 683 13% 466 14% 104 14% 74 19% 43 15% 53 14% 5 423 13%
Page 14 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 16
For peer review only
15
Unknown 1 069 3% 84 3% 14 2% 23 6% 24 8% 14 4% 1 228 3%
Census-tract SES
Q1 (Low) 4 672 13% 508 15% 124 17% 55 14% 49 17% 58 15% 5 466 13%
Q2 5 904 16% 579 18% 133 18% 73 19% 61 21% 74 20% 6 824 17%
Q3 7 063 20% 618 19% 143 20% 75 20% 55 19% 66 18% 8 020 20%
Q4 8 134 23% 721 22% 151 21% 88 23% 47 17% 79 21% 9 220 22%
Q5 (High) 9 685 27% 811 25% 162 22% 82 22% 63 22% 97 26% 10 900 27%
Unknown 562 2% 51 2% * * * * * * * * 642 2%
Total 36 020 88% 3 288 8% 722 2% 381 1% 284 1% 377 1% 41 072 100%
*SEER 18 registries excluding Louisiana and Alaska and 232 cases with poorly specified histologies. Case counts suppressed to conceal cells with 10 or fewer cases.
†White, black, and API exclude persons of Hispanic ethnicity.
Abbreviations: API = Asian/Pacific Islander; cm = centimeter; NOS = not otherwise specified; Q = quintile; SEER = Surveillance, Epidemiology, and End Results.
Page 15 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 17
For peer review only
16
Table 2. Papillary thyroid cancer incidence rates and rate ratios by SES and tumor size among fully insured cases,
SEER registries, 2007-2010*
All cases ≤2 cm tumors
SES No. Rate‡ RR 95% CI No. Rate RR 95% CI
26 392 18 539
Q1(Low) 2 664 4.6 1.0 (Referent) 1 778 3.1 1.0 (Referent)
Q2 4 045 6.5 1.4 (1.4–1.5) 2 722 4.4 1.4 (1.3–1.5)
Q3 5 248 8.1 1.8 (1.7–1.9) 3 643 5.6 1.8 (1.7–1.9)
Q4 6 425 9.6 2.1 (2.0–2.2) 4 573 6.8 2.2 (2.1–2.3)
Q5(High) 8 011 11.6 2.6 (2.4–2.7) 5 823 8.4 2.7 (2.6–2.9)
Trend for SES <.0001 <.0001
*SEER 18 excluding Alaska and Louisiana and cases with unknown SES.
†Fully Insured: Private Insurance; Fee-for-Service; Private Insurance: Managed care, HMO, or PPO; TRICARE; Medicare
Administered through a Managed Care plan; Medicare with private supplement; Medicare with supplement, NOS; and Military;
Other: Uninsured; Any Medicaid; Insured, No Specifics; and Insurance status unknown.
‡Age-adjusted rates adjusted to the 2000 US standard population.
Abbreviations: CI = confidence interval; cm = centimeter; Q = quintile; RR = rate ratio; SEER = Surveillance, Epidemiology,
and End Results; SES = census tract socioeconomic status.
Page 16 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 18
For peer review only
17
Table 3. Papillary thyroid cancer incidence rates and rate ratios by SES, age, race, and gender among fully insured
cases with ≤2 cm tumors, SEER registries, 2007-2010*
Attribute Group/Trend for SES SES Count Rate Rate Ratio 95% Confidence Interval
Age Group
00-49 Years
p=0.0003
03
Q1(Low) 850 2.0 1.0 (Ref)
Q2 1 298 3.0 1.5 (1.4, 1.6)
Q3 1 833 4.2 2.1 (1.9, 2.2)
Q4 2 289 5.1 2.5 (2.3, 2.7)
Q5(High) 2 955 6.7 3.3 (3.0, 3.5)
50-64 Years
p<0.0001 Q1(Low) 596 6.2 1.0 (Ref)
Q2 933 8.9 1.4 (1.3, 1.6)
Q3 1 229 10.7 1.7 (1.6, 1.9)
Q4 1 606 13.2 2.1 (2.0, 2.4)
Q5(High) 2 084 15.6 2.5 (2.3, 2.8)
65+ Years
p=0.0008 Q1(Low) 332 5.2 1.0 (Ref)
Q2 491 6.8 1.3 (1.1, 1.5)
Q3 581 7.5 1.5 (1.3, 1.7)
Q4 678 8.6 1.7 (1.5, 1.9)
Q5(High) 784 9.5 1.8 (1.6, 2.1)
Race
White
p<0.0001 Q1(Low) 1 416 3.5 1.0 (Ref)
Q2 2 245 4.7 1.3 (1.2, 1.4)
Page 17 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 19
For peer review only
18
Q3 3 096 6.0 1.7 (1.6, 1.8)
Q4 3 883 7.2 2.1 (1.9, 2.2)
Q5(High) 4891 8.8 2.5 (2.4, 2.7)
Black
p=0.0025 Q1(Low) 247 1.9 1.0 (Ref)
Q2 198 2.6 1.3 (1.1, 1.6)
Q3 181 3.0 1.5 (1.3, 1.9)
Q4 147 3.4 1.8 (1.4, 2.2)
Q5(High) 117 4.5 2.3 (1.8, 2.9)
Asian
p=0.0199 Q1(Low) 84 2.4 1.0 (Ref)
Q2 248 4.9 2.1 (1.6, 2.7)
Q3 312 4.8 2.0 (1.6, 2.6)
Q4 478 5.5 2.3 (1.8, 3.0)
Q5(High) 716 6.6 2.8 (2.2, 3.5)
Gender
Male
p= 0.0014 Q1(Low) 318 1.1 1.0 (Ref)
Q2 491 1.7 1.4 (1.2, 1.7)
Q3 689 2.2 1.9 (1.7, 2.2)
Q4 888 2.7 2.4 (2.1, 2.7)
Q5(High) 1 266 3.7 3.2 (2.8, 3.7)
Female
p<0.0001 Q1(Low) 1 460 4.9 1.0 (Ref)
Q2 2 231 7.0 1.4 (1.3, 1.5)
Page 18 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 20
For peer review only
19
Q3 2 954 8.9 1.8 (1.7, 1.9)
Q4 3 685 10.7 2.2 (2.1, 2.3)
Q5(High) 4 557 12.8 2.6 (2.5, 2.8)
*SEER 18 excluding Alaska and Louisiana and cases with unknown SES.
†Fully Insured: Private Insurance; Fee-for-Service; Private Insurance: Managed care, HMO, or PPO; TRICARE; Medicare
Administered through a Managed Care plan; Medicare with private supplement; Medicare with supplement, NOS; and Military;
Other: Uninsured; Any Medicaid; Insured, No Specifics; and Insurance status unknown.
‡Age-adjusted rates adjusted to the 2000 US standard population.
Abbreviations: cm = centimeter; Q = quintile;; SEER = Surveillance, Epidemiology, and End Results; SES = census tract
socioeconomic status.
Page 19 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 21
For peer review only
20
Figure 1
Page 20 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 22
For peer review only
1
STROBE Research checklist of items included in this manuscript
Item
No Recommendation
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done
and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any prespecified hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment,
exposure, follow-up, and data collection
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of
case ascertainment and control selection. Give the rationale for the choice of cases
and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of
selection of participants
(b) Cohort study—For matched studies, give matching criteria and number of
exposed and unexposed
Case-control study—For matched studies, give matching criteria and the number of
controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable
Data sources/
measurement
8* For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if there
is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was
addressed
Cross-sectional study—If applicable, describe analytical methods taking account of
sampling strategy
(e) Describe any sensitivity analyses
Continued on next page
Page 21 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 23
For peer review only
2
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive
data
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information
on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time
Case-control study—Report numbers in each exposure category, or summary measures of
exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
time period
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
analyses
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision.
Discuss both direction and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
of analyses, results from similar studies, and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable,
for the original study on which the present article is based
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and
unexposed groups in cohort and cross-sectional studies.
I affirm on this 26th day of August, 2015 that the items included in the STROBE checklist have been addressed in the
manuscript submitted to BMJ Open, “Does US Thyroid Cancer Incidence Increase with Socioeconomic Status and
Health Insurance?”
Sean Altekruse, DVM, MPH, PhD
National Cancer Institute
Division of Cancer Control and Population Sciences
Surveillance Research Program
Rockville, MD
Page 22 of 22
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 24
For peer review only
Do US Thyroid Cancer Incidence Rates Increase with
Socioeconomic Status among People with Health Insurance?
An observational study using SEER population-based data
Journal: BMJ Open
Manuscript ID bmjopen-2015-009843.R1
Article Type: Research
Date Submitted by the Author: 21-Oct-2015
Complete List of Authors: Altekruse, Sean; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences Das, Anita; National Cancer Institute, Surveillance Research Program,
Division of Cancer Control and Population Sciences Cho, Hyunsoon; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences; National Cancer Center, Division of Cancer Registration and Surveillance Petkov, Valentina; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences Yu, Mandi; National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences
<b>Primary Subject Heading</b>:
Oncology
Secondary Subject Heading: Epidemiology
Keywords: Endocrine tumours < ONCOLOGY, Epidemiology < ONCOLOGY, PUBLIC
HEALTH
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open on A
pril 25, 2022 by guest. Protected by copyright.
http://bmjopen.bm
j.com/
BM
J Open: first published as 10.1136/bm
jopen-2015-009843 on 7 Decem
ber 2015. Dow
nloaded from
Page 25
For peer review only
1
Do US Thyroid Cancer Incidence Rates Increase with Socioeconomic Status among People with Health
Insurance? An observational study using SEER population-based data
Sean Altekruse1, Anita Das1, Hyunsoon Cho1,2, Valentina Petkov1, Mandi Yu1
1. National Cancer Institute, Surveillance Research Program, Division of Cancer Control and Population Sciences
Rockville, Maryland, United States
2. National Cancer Center, Division of Cancer Registration and Surveillance
Goyang, Korea (the Republic of)
Abstract: 238 words
Text: 2 259 words
Tables: 3
Figures: 1
References: 34
Running header: Thyroid cancer, socioeconomic, and insurance status
Correspondence to: Sean F. Altekruse, Surveillance Research Program, Division of Cancer Control and Population
Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive 4E536, Rockville MD
20850
Telephone: 240.276.6933
Fax: 240.276.7908
E-mail: [email protected]
Page 1 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 26
For peer review only
2
Abstract
Objectives: United States thyroid cancer incidence rates are rising while mortality remains stable. Trends are driven
by papillary thyroid cancer (PTC), the predominant cancer subtype which has a very good prognosis. We
hypothesized that health insurance and high census tract socioeconomic status (SES) are associated with PTC risk.
Design: Relationships between thyroid cancer incidence, insurance and census-tract socioeconomic status (SES)
during 2007-2010 were examined in population-based cancer registries. Cases were stratified by tumor histology,
size and demography.
Setting: Surveillance, Epidemiology, and End Results (SEER) registries covering 30% of the US population.
Results: PTCs accounted for 88% of incident thyroid cancer cases. Small PTCs (≤2 cm) accounted for 60% of
cases. Unlike non-PTC cases the majority of those diagnosed with PTC were <50 years of age and had ≤2 cm
tumors. Rate ratios (RR) of PTC diagnoses increased monotonically with SES among fully insured cases. The effect
was strongest for small PTCs, high- versus low-SES quintile RR=2.7, 95% confidence interval (CI): 2.6–2.9, two-
sided trend test P < 0.0001. For small PTC cases with insurance the monotonic increase in incidence rates with
rising SES persisted among cases younger than 50 years of age (RR=3.3, 95% CI=3.0–3.5), women (RR=2.6, 95%
CI=2.5–2.8) and whites (RR=2.5, 95% CI=2.4–2.7). Among the less than fully insured, rates generally decreased
with increasing SES.
Conclusion: The greater than 2.5 fold increase in risk of PTC diagnosis among insured individuals associated with
high SES may be informative with respect to the contemporary issue of papillary thyroid cancer overdiagnosis.
Strengths and limitations of this study
• The study included 41 072 incident thyroid cancer case during 2007-2010 across 30% of the US population.
• Rate ratios and confidence intervals were used to assess effects of SES and insurance on thyroid cancer incidence.
• Effects were also examined by patient attributes, tumor size, and histology.
• Potential misclassification of histology data from population-based pathology reports was a limitation of this study.
Page 2 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 27
For peer review only
3
Introduction
In Surveillance, Epidemiology, and End Results (SEER) registry areas of the United States from 1975–2011,
thyroid cancer incidence rates tripled (1-3) while US thyroid cancer mortality trends were steady (1). These
discrepant trends are consistent with cancer overdiagnosis (2-4). Similar patterns are reported in many but not all
industrialized countries (3). Thyroid cancer incidence rates are higher among women than men (5) and among
whites than other major racial groups (6,7). Most of the rising incidence results from the increasing diagnosis of
small papillary thyroid cancers (PTCs) (2-4,8-10).
Access to health insurance contributes to the overdiagnosis of small PTCs (3,11-13) which carry relatively low
risk of death (3). Incidence rates of small PTCs are elevated in high-socioeconomic status (SES) counties (7,14,15)
and census tracts (11,12). Overdiagnosis and overtreatment of PTCs are associated with adverse effects, including
postsurgical complications, extended hospitalization, and lifelong hormone replacement therapy (2-4,16). In
contrast, several non-PTC types, including follicular, medullary, and anaplastic thyroid cancers carry progressively
worse prognoses (17). The present analysis, based on population-level cancer registry data covering approximately
30% of the United States, demonstrates the magnitude of combined effects of neighborhood socioeconomic status,
or SES (18, 19), and personal insurance status on the overdiagnosis of small PTCs including by age, gender, race
and ethnicity.
Materials and Methods
Data were obtained from 16 National Cancer Institute (NCI) SEER registries that cover approximately 30% of
the US population. The SEER November 2012 dataset was used for all analyses. Registries included in analyses
were Connecticut, Detroit, Hawaii, San Francisco-Oakland, Atlanta, Iowa, New Mexico, Seattle-Puget Sound, Utah,
Los Angeles, San Jose-Monterey, Rural Georgia, Greater California, Greater Georgia, Kentucky, and New Jersey.
Alaska Native cases were excluded because census-tract attributes were not available, and Louisiana cases were
excluded because of uncertainty about the population impact of Hurricane Katrina on census tract SES.
Case Attributes
Gender and age distributions (<50 years, 50–64 years, and ≥65 years of age at diagnosis) were examined.
While 98% of cases were 20 years of age and older at time of diagnosis, the analysis included children less than 20
years of age for purpose of completeness. Race and ethnicity were defined as Hispanic, non-Hispanic white, non-
Page 3 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 28
For peer review only
4
Hispanic black, and non-Hispanic Asian/Pacific Islander. Non-Hispanic American Indian/Alaska Natives and other
and unknown race were combined as one group. Tumors were classified as ≤2cm, >2cm, and unknown size. When
≤10 cases were observed data were suppressed.
Histologic Classification
Only malignant primary thyroid cancers were included in analyses. Thyroid cancer histologic classifications
were coded using the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) (20). A total of
283 cases with poorly specified cancer histologies (ICD-O-3 morphologies 8000–8005) were excluded. ICD-O-3
histology codes for papillary thyroid cancer were 8050,8052,8260,8340,8341,8342,8343,8344. Other types were
follicular (8290,8330,8331,8332,8335), medullary (8290,8330,8331,8332,8335) and anaplastic thyroid cancer
(8012,8020-8021,8030-8032). Approximately 2% of cases were diagnosed with non-classical thyroid cancer
histologies including 284 cases (1%) with other epithelial neoplasms (8010,8013,8015,8022,8033,8035,8041,8046)
and 377 cases (1%) with other rare specified primary thyroid cancer histologies (8070-8072,8074,8082-
8083,8130,8140-8141,8190,8200-8201,8230,8240,8246,8255,8262-8263,8310,8323,8337,8347,8350,8430,8450,
8452,8460,8480-8481,8504,8507,8560,8570,8588-8589,8800,8802,8810,8830,8890,8980,9040-9041,9071,9080,
9120,9250,9364). These included adenocarcinomas and squamous cell carcinoma, which are referenced on the
SEER thyroid/histology validation list (21) and other specified histologies that are not found in the SEER validation
list but were abstracted from patients’ medical records.
Insurance
SEER data include the six category variable “Insurance Recode” for diagnosis year 2007 forward, derived from
the more detailed “Primary Payer at Diagnosis” variable. For the purpose of the present analysis, categories were
collapsed into “Fully Insured,” and “Other than Fully Insured.” “Fully Insured” is defined by the following seven
categories of health insurance: 1. Insured - Private Insurance: Fee-for-Service, 2. Private Insurance: Managed care,
3. HMO or PPO, 4. TRICARE, 5. Medicare - Administered through a Managed Care plan, 6. Medicare with private
supplement, 7. Medicare with supplement, NOS and 7. Military. “Other than Fully Insured,” included 1. Uninsured
cases; 2. Cases with Medicaid, Indian Health Service insurance and 3. Patients reported to be insured without further
information available. The 1,228 cases with missing data on insurance status were excluded from insurance-related
analyses.
Page 4 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 29
For peer review only
5
Census-Tract Level SES
SES is typically measured using county-level attributes as a proxy for individual data. However, county-level
SES attributes are less precise than smaller-area or individual SES attributes. To improve area-based SES estimates,
we used a year-dependent census-tract SES composite index (18) linked to SEER cases by the census tracts of
residence at time of diagnosis. The SES index was derived from seven variables (percent working class population,
percent adult unemployment, educational attainment, median household income, percent of population living below
150% of national poverty line, median rent, and median home value). Taken together these variables capture three
principal components of SES (income, occupation, education). The weight assigned to each variable was determined
based on factor analysis (18). Specifically, the output from factor analysis that explained more than 90% of common
variance among these variables was used as the “SES index.” This index was constructed separately for 2007, 2008,
2009, and 2010 using the 5-year estimates from the 2005–2009, 2006–2010, 2007–2011, and 2008–2012 American
Community Surveys, respectively. Census tracts were categorized into SES quintiles according to this index, with
equal populations in each quintile. The first quintile (Q1, lowest SES) is the 20th percentile or less, and the fifth
quintile (Q5, highest SES) corresponds to the 80th percentile or higher. The SES index used in the present study has
the advantage over specific area level SES measures of protecting against disclosure of case identity through
identification of any census tract with a unique permutation of multiple SES attributes. The index is linked to
standard SEER data and is available for public use upon request from the authors. A total of 642 cases were missing
data on SES and were excluded from SES-related analysis.
Incidence by Insurance and SES
Age-adjusted incidence rates (22) were calculated by tumor size, insurance status, SES, and histology for cases
diagnosed during 2007–2010, years during which insurance data were available (SEER*Stat version 8.1.5, IMS,
Inc., Calverton, MD). Thyroid cancer incidence rates per 100 000 persons were directly age-adjusted to the 2000 US
population. Rate ratios (RR) and 95% confidence intervals (CIs) were calculated using the SES lowest quintile as
the reference. Regression models were used to estimate the percentage change in rate by SES (23) for PTC and non-
PTC histologies using the SAS PROC REG procedure (SAS 9.3, Cary, NC). The regression line slope was
considered to be statistically different from zero at a cutoff of p ≤ 0.05 based on a two-sided test.
Page 5 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 30
For peer review only
6
Results
Demographics
Characteristics of patients diagnosed with thyroid cancer during 2007–2010 are shown in Table 1. The 41 072
cases were diagnosed with the following subtypes: 36 020 papillary (88%), 3 288 follicular (8%), 722 medullary
(2%), 381 anaplastic (1%), 284 other epithelial (1%), and 377 other histologies (1%). Half of cases (49%) were less
than 50 years of age, including 51% of PTC cases. Most cases in other histologic groups were 50 years of age or
older. Women accounted for 76% of cases and 77% of PTC cases. Asian/Pacific Islander accounted for a high
proportion of anaplastic tumors (13%), while blacks accounted for a high proportion of follicular, medullary (9%
each), and other epithelial tumors (10%). Among whites and Hispanics, subtype distributions were similar to overall
thyroid cancer case distributions. Most PTCs (69%) were ≤2 cm (small PTCs). Small PTCs accounted for 24 745 of
all 41 072 thyroid cancer cases (60%). Most follicular thyroid (69%) and most anaplastic thyroid cancer (76%)
tumors were >2cm in size. PTC cases had the highest percentage of full insurance coverage (74%). The percentage
of full insurance coverage ranged from 60% for anaplastic and other epithelial to 72% for follicular cancer cases.
Insurance data were missing for 3% of cases. Analysis of SES was based on 40 430 cases, with missing SES data for
642 cases. Case counts increased with SES for each subtype, doubling for PTC from quintile 1 to 5, increasing by
60% for follicular, 31% for medullary, 49% for anaplastic, 29% for other epithelial, and 67% for other specified
cancers.
Insurance and SES
Among fully insured cases RRs for PTC incidence increased monotonically with SES (Table 2). The RR in the
high compared to the low SES stratum was 2.6 (95% CI: 2.4–2.7), two-sided trend test of rate, P < 0.0001. For small
PTCs this RR reached 2.7 (95% CI: 2.6–2.9), two-sided trend test P < 0.0001. Incidence rates for larger PTCs were
lower than those for small PTCs and the dose response with rising SES was attenuated compared to that of small
PTCs. The monotonic increase in RR with increasing SES for PTC cases persisted for small PTCs including among
persons less than 50 years of age, women and whites (Table 3). RRs associated with high SES and insurance are
shown in red while those of less than fully insured cases are shown in blue in Figures 1 and 2. In addition to the
overall effect among insured cases (Figure 1) large increases in RRs with SES were seen among persons <50 years
of age, men, and Asians (Figure 2). Among insured non-PTC cases the increase in RRs with SES was less
Page 6 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 31
For peer review only
7
pronounced than among cases with PTCs, with follicular tumors accounting for 60% of non-PTCs. Among less than
fully insured cases rates did not increase with SES.
Page 7 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 32
For peer review only
8
Discussion
In this SEER study among fully insured cases, risk of PTC diagnosis increased monotonically with SES. This
association was driven by diagnosis of small PTCs, with a 2.7-fold higher rate in the highest compared to the lowest
SES quintile. The effect persisted within several subgroups including persons less than 50 years of age, women, and
whites. These overlapping subgroups comprise a large proportion of all cases, with large numbers of subjects in each
SES stratum. Among the “other than fully insured,” a more heterogeneous group including Medicaid and uninsured
patients, thyroid cancer incidence did not increase with SES. The enumeration of risk among insured cases in high
compared to low SES areas may inform current discussions pertaining to PTC overdiagnosis.
The present study is a large SEER population-based study, covering 30% of the population, with both census-
tract SES and individual insurance data. The results are more detailed than previous studies of thyroid cancer
incidence and SES (3,7,11-15,24) or health insurance coverage (12-15) with findings that differ from early studies
that found no association with SES or insurance (25,26). Our study and a New Jersey study spanning 1979–2006
(12) include census tract-level SES. The New Jersey study included county-level insurance data, while the present
study is based on individual-level insurance data. This is the first report of which we are aware to report a monotonic
increase in PTC incidence rates with rising SES among insured cases. Our findings further indicate that this effect is
largely driven by the diagnosis of small PTCs.
The rising incidence of small PTCs is described as an epidemic of diagnosis (2-4), disproportionately affecting
women (4,5,11,12) and patients under 50 years of age (5). Among insured cases the effect of SES on risk of small
PTC diagnosis was most pronounced among persons less than 50 years of age. There is a need to determine why
people in this age stratum and other at-risk groups including women and whites are more likely to undergo tests that
lead to the diagnosis of PTC. Although small PTCs accounted for 60% of thyroid cancer cases in this report,
previous studies indicate PTCs account for less than 5% of thyroid cancer deaths and that other thyroid cancer types
carry far worse prognoses (17). The higher incidence of PTC among insured individuals residing in high SES areas
could be a consequence of higher paid individuals being “overinsured” relative to lower paid “underinsured”
workers (27). Overinsurance could increase access to imaging and biopsy for cancer screening and evaluation of
benign thyroid conditions. Such technologies may detect small, relatively low-risk thyroid nodules (2,4). In one
study, areas with high numbers of young physicians reported increased incidence rates of thyroid cancer compared
Page 8 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 33
For peer review only
9
to areas with high concentrations of older physicians (28). The authors postulated that there is greater use of
ultrasound-guided biopsy by young physicians trained in this technology. If these diagnostic resources are more
likely to be found in high SES areas, it could contribute to associations between affluence and PTC incidence. Other
potential explanations include that income and insurance are proxy measures for education. To the extent that this is
the case, more educated individuals may seek early care and press their physicians for specific thyroid-related tests
and treatments.
Unless needed, post-diagnosis thyroidectomy and radiation place patients with small PTCs at risk for avoidable
surgical complications, lifetime thyroid replacement therapy, and perhaps second malignancies (2-4). The cost of
care for US patients diagnosed with well-differentiated thyroid cancer exceeded $1.6 billion in 2013 alone, including
more than $0.5 billion each for initial treatment and continued follow-up (29). American Thyroid Association
(ATA) Management guidelines (30) for patients with thyroid nodules encourage non-invasive management unless
patients have risk factors such as a family history of thyroid cancer, specific medical or environmental radiation
exposures, or rapid tumor growth with hoarseness. One recent study estimated that, in the United States,
approximately 82 000 men and women were diagnosed with papillary thyroid cancers during 1981-2011 that would
never cause symptoms (31). It has been proposed that some small PTCs be reclassified as non-cancers (2,3,10) or
that the most biologically indolent tumors be managed with watchful waiting (2-4). Reclassifying any PTCs as non-
cancerous would affect cancer survival statistics (32), because thyroid cancer survival is known to vary by stage,
age, gender and treatment (33). Biomarker research may also help to distinguish thyroid cancers including PTCs that
are likely to exhibit aggressive behavior from other, more indolent types (34).
Strengths of this study include availability of SEER variables for census-tract SES and individual insurance
status in registries covering 30% of the US population. Most studies of thyroid cancer incidence and SES (3,7,11,13-
15,24) have measured SES at the county or registry level. Study limitations include potential misclassification of
histology and availability of insurance data only for 4 recent years. In summary, compared to persons with insurance
living in low SES areas, those from high SES areas had more than a 2.5 fold higher risk of being diagnosed with
PTC. The association was driven by small PTCs and persisted among persons younger than 50 years, women and
whites. Quantifying the risk of PTC associated with SES and insurance may inform efforts to prevent overdiagnosis.
Data Sharing
Page 9 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 34
For peer review only
10
The SES index used in this report is linked to the SEER public research dataset and is available from the authors
upon review of request.
Page 10 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 35
For peer review only
11
References
1. NCI. SEER Cancer Statistics Review, 1975–2011. http://seer.cancer.gov/csr/1975_2011/. Accessed October 7,
2014.
2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg.
2014;140(4):317–322.
3. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of
low risk tumours. BMJ. 2013;347:4706.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA.
2006;295(18):2164–2167.
5. Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the
thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092–1100.
6. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United
States by histologic type, 1992-2006. Thyroid. 2011;21(2):125–134.
7. Morris LG, Sikora AG, Myssiorek D, DeLacure MD. The basis of racial differences in the incidence of thyroid
cancer. Ann Surg Oncol. 2008;15(4):1169–1176.
8. Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am.
2012;96(2):369–383.
9. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated
thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357–1361.
10. How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ.
2007;177(11):1383–1384.
11. Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer
in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11(12):163–170.
12. Roche LM, Niu X, Pawlish KS, Henry KA. Thyroid cancer incidence in New Jersey: time trend, birth cohort
and socioeconomic status analysis (1979-2006). J Environ Public Health. 2011;2011:850105.
13. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of
access to care. Thyroid. 2013;23(7):885–891.
Page 11 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 36
For peer review only
12
14. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer
incidence in the United States: review of incidence trends by socioeconomic status within the Surveillance,
Epidemiology, and End Results registry, 1980-2008. Thyroid. 2013;23(1):103–110.
15. Sprague BL, Warren Andersen S, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of
health care access. Cancer Causes Control. 2008;19(6):585–593.
16. Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am.
1989;18(2):359–387
17. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP. Thyroid cancer incidence and survival in the National
Cancer Institute Surveillance, Epidemiology, and End Results race/ethnicity groups. Thyroid. 2010;20(5):465–473.
18. Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate
health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014;25(1):81–
92.
19. Yost K, Perkins C, Cohen R, Morris C, Wright W.Socioeconomic status and breast cancer incidence in
California for different race/ethnic groups. Cancer Causes Control. 2001 Oct;12(8):703-11.
20. Percy C, Fritz A, Jack A, et al, eds. International classification of diseases for oncology (ICD-O). 3rd ed.
Geneva, Switzerland: World Health Organization; 2000.
21. NCI. ICD-O-3 SEER Site/Histology Validation List http://seer.cancer.gov/icd-o-3/. Accessed June 30, 2015
22. National Cancer Institute. Standard Populations (Millions) for Age-Adjustment Website; 2013.
http://seer.cancer.gov/stdpopulations/. Accessed October 7, 2014.
23. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort
studies. IARC Sci Publ. 1987;(82):1–406.
24. Hall SF, Irish J, Groome P, Griffiths R. Access, excess, and overdiagnosis: the case for thyroid cancer. Cancer
Med. 2014;3(1):154–161.
25. Haselkorn T, Stewart SL, Horn-Ross PL. Why are thyroid cancer rates so high in Southeast Asian women living
in the United States? The Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev. 2003;12(2):144–150.
26. Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW. An epidemiologic study of thyroid cancer in
Hawaii. Cancer Causes Control. 1990;1(3):223–234.
Page 12 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 37
For peer review only
13
27. Robertson CT. Scaling cost-sharing to wages: how employers can reduce health spending and provide greater
economic security. Yale J Health Policy Law Ethics. 2014;14(2):239-95.
28. Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH. Age of diagnosing physician impacts the
incidence of thyroid cancer in a population. Cancer Causes Control. 2014; 25(12):1627–1634.
29. Lubitz CC, Kong CY, McMahon PM, et al. Annual financial impact of well-differentiated thyroid cancer care in
the United States. Cancer. 2014;120(9):1345–1352.
30. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
31. O’Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the united states
1981-2011. Int J Cancer. 2015 Jun 9. doi: 10.1002/ijc.29634. [Epub ahead of print]
32. Ho AS, Davies L, Nixon IJ, et al. Cancer. Increasing diagnosis of subclinical thyroid cancers leads to spurious
improvements in survival rates. 2015 Jun 1;121(11):1793-9.
33. Banerjee M, Muenz DG, Worden F, Wong SL, Haymart MR. Conditional survival in thyroid cancer patients
[published online ahead of print October 8, 2014]. Thyroid. 2014; 24(12):1784–1789.
34. Baldini E, Sorrenti S, Tuccilli C, et al. Emerging molecular markers for the prognosis of differentiated thyroid
cancer patients. Int J Surg. 2014;12(suppl 1):S52–S56.
Page 13 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 38
For peer review only
14
Figure Legends
Figure 1. Overall and age-specific thyroid cancer rate ratios by SES and insurance status for papillary thyroid
cancers (PTC) and other histologies with stratification of PTCs <2 cm in size-- SEER registries, 2007-2010*
*SEER 18 excluding Louisiana and Alaska cases and 283 cases with unspecified histologies (ICD-O-3 8000–8005).
Figure 2. Gender- and race-specific thyroid cancer rate ratios by SES and insurance status for papillary thyroid
cancers (PTC) and other histologies with stratification of PTCs <2 cm in size-- SEER registries, 2007-2010*
*SEER 18 excluding Louisiana and Alaska cases and 283 cases with unspecified histologies (ICD-O-3 8000–8005).
API: Asian/Pacific Islander
Author's contributions
Sean Altekruse: Design; acquisition, analysis, and interpretation of data. Drafting and revising for important
intellectual content. Final approval of the version to be published; and agreement to be accountable for the accuracy
and integrity of any part of the work.
Anita Das: Design; acquisition and interpretation of data. Final approval of the version to be published; and
agreement to be accountable for the accuracy and integrity of any part of the work.
Hyunsoon Cho: Design; analysis, and interpretation of data. Drafting and revising of content. Final approval of the
version to be published; and agreement to be accountable for the accuracy and integrity of any part of the work.
Valentina Petkov: Analysis, and interpretation of data. Drafting and revising of content. Final approval of the
version to be published; and agreement to be accountable for the accuracy and integrity of any part of the work.
Mandi Yu: Design, acquisition, analysis, and interpretation of data. Drafting and revising for important intellectual
content. Final approval of the version to be published; and agreement to be accountable for the accuracy and
integrity of any part of the work.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Page 14 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 39
For peer review only
15
Competing Interests
The authors have no conflicts of interest to declare.
Data sharing
No additional data available.
Page 15 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 40
For peer review only
16
Table 1. Characteristics of thyroid cancer cases by histologic group, SEER registries 2007–2010*
Histology groups
Papillary Follicular Medullary Anaplastic Other
epithelial
Other
specified
Total
No. % No. % No. % No. % No. % No. % No. %
Diagnosis age
<50 years 18 358 51% 1 333 41% 279 39% 20 5% 65 23% 136 36% 20 191 49%
50–64 years 11 603 32% 1 026 31% 238 33% 90 24% 67 24% 117 31% 13 141 32%
65+ years 6 059 17% 929 28% 205 28% 271 71% 152 54% 124 33% 7 740 19%
Sex
Female 27 906 77% 2 304 70% 445 62% 233 61% 186 65% 257 68% 31 331 76%
Male 8 114 23% 984 30% 277 38% 148 39% 98 35% 120 32% 9 741 24%
Race/ethnicity†
White† 24 285 67% 2 241 68% 494 68% 264 69% 182 64% 251 67% 27 717 67%
Page 16 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 41
For peer review only
17
Hispanic 5 540 15% 412 13% 108 15% 45 12% 34 12% 47 12% 6 186 15%
API† 3 684 10% 264 8% 35 5% 51 13% 32 11% 34 9% 4 100 10%
Black† 1 930 5% 312 9% 68 9% 18 5% 28 10% 34 9% 2 390 6%
Other 581 2% 59 2% 17 2% * * * * 11 3% 679 2%
Tumor size (cm)
≤2cm 24 745 69% 784 24% 347 48% * * * * 154 41% 26 083 64%
>2cm 9 907 28% 2 271 69% 326 45% 289 76% 106 37% 172 46% 13 071 32%
Unknown 1 368 4% 233 7% 49 7% 83 22% 134 47% 51 14% 1 918 5%
Insurance status
Fully insured 26 800 74% 2 366 72% 497 69% 227 60% 169 60% 265 70% 30 324 74%
Uninsured 847 2% 83 3% 27 4% * * * * * * 985 2%
Any Medicaid 2 621 7% 289 9% 80 11% 47 12% 40 14% 35 9% 3 112 8%
Insured, NOS 4 683 13% 466 14% 104 14% 74 19% 43 15% 53 14% 5 423 13%
Page 17 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 42
For peer review only
18
Unknown 1 069 3% 84 3% 14 2% 23 6% 24 8% 14 4% 1 228 3%
Census-tract SES
Q1 (Low) 4 672 13% 508 15% 124 17% 55 14% 49 17% 58 15% 5 466 13%
Q2 5 904 16% 579 18% 133 18% 73 19% 61 21% 74 20% 6 824 17%
Q3 7 063 20% 618 19% 143 20% 75 20% 55 19% 66 18% 8 020 20%
Q4 8 134 23% 721 22% 151 21% 88 23% 47 17% 79 21% 9 220 22%
Q5 (High) 9 685 27% 811 25% 162 22% 82 22% 63 22% 97 26% 10 900 27%
Unknown 562 2% 51 2% * * * * * * * * 642 2%
Total 36 020 88% 3 288 8% 722 2% 381 1% 284 1% 377 1% 41 072 100%
*SEER 18 registries excluding Louisiana and Alaska and 232 cases with poorly specified histologies. Case counts suppressed to conceal cells with 10 or fewer cases.
†White, black, and API exclude persons of Hispanic ethnicity.
Abbreviations: API = Asian/Pacific Islander; cm = centimeter; NOS = not otherwise specified; Q = quintile; SEER = Surveillance, Epidemiology, and End Results.
Page 18 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 43
For peer review only
19
Table 2. Papillary thyroid cancer incidence rates and rate ratios by SES and tumor size among fully insured cases, SEER registries, 2007-2010*
All cases ≤2 cm tumors >2 cm tumors
SES No. Rate‡ RR 95% CI No. Rate RR 95% CI No. Rate RR 95% CI
26 392 18 539 6 774
Q1(Low) 2 664 4.6 1.0 (Referent) 1 778 3.1 1.0 (Referent) 484 1.3 1.0 (Referent)
Q2 4 045 6.5 1.4 (1.4–1.5) 2 722 4.4 1.4 (1.3–1.5) 1 205 1.9 1.5 (1.3, 1.6)
Q3 5 248 8.1 1.8 (1.7–1.9) 3 643 5.6 1.8 (1.7–1.9) 1 457 2.3 1.7 (1.6, 1.9)
Q4 6 425 9.6 2.1 (2.0–2.2) 4 573 6.8 2.2 (2.1–2.3) 1 670 2.5 1.9 (1.7, 2.1)
Q5(High) 8 011 11.6 2.6 (2.4–2.7) 5 823 8.4 2.7 (2.6–2.9) 1 958 2.9 2.2 (2.0, 2.4)
Trend for SES <.0001 <.0001 0.002
*SEER 18 excluding Alaska and Louisiana and cases with unknown SES.
†Fully Insured: Private Insurance; Fee-for-Service; Private Insurance: Managed care, HMO, or PPO; TRICARE; Medicare Administered through a Managed Care plan; Medicare
with private supplement; Medicare with supplement, NOS; and Military; Other: Uninsured; Any Medicaid; Insured, No Specifics; and Insurance status unknown.
‡Age-adjusted rates adjusted to the 2000 US standard population.
Abbreviations: CI = confidence interval; cm = centimeter; Q = quintile; RR = rate ratio; SEER = Surveillance, Epidemiology, and End Results; SES = census tract socioeconomic
status.
Page 19 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 44
For peer review only
20
Table 3. Papillary thyroid cancer incidence rates and rate ratios by SES, age, race, and gender among fully insured
cases with ≤2 cm tumors, SEER registries, 2007-2010*
Attribute Group/Trend for SES SES Count Rate Rate Ratio 95% Confidence Interval
Age Group
00-49 Years
p=0.0003
03
Q1(Low) 850 2.0 1.0 (Ref)
Q2 1 298 3.0 1.5 (1.4, 1.6)
Q3 1 833 4.2 2.1 (1.9, 2.2)
Q4 2 289 5.1 2.5 (2.3, 2.7)
Q5(High) 2 955 6.7 3.3 (3.0, 3.5)
50-64 Years
p<0.0001 Q1(Low) 596 6.2 1.0 (Ref)
Q2 933 8.9 1.4 (1.3, 1.6)
Q3 1 229 10.7 1.7 (1.6, 1.9)
Q4 1 606 13.2 2.1 (2.0, 2.4)
Q5(High) 2 084 15.6 2.5 (2.3, 2.8)
65+ Years
p=0.0008 Q1(Low) 332 5.2 1.0 (Ref)
Q2 491 6.8 1.3 (1.1, 1.5)
Q3 581 7.5 1.5 (1.3, 1.7)
Q4 678 8.6 1.7 (1.5, 1.9)
Q5(High) 784 9.5 1.8 (1.6, 2.1)
Race
White
p<0.0001 Q1(Low) 1 416 3.5 1.0 (Ref)
Q2 2 245 4.7 1.3 (1.2, 1.4)
Page 20 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 45
For peer review only
21
Q3 3 096 6.0 1.7 (1.6, 1.8)
Q4 3 883 7.2 2.1 (1.9, 2.2)
Q5(High) 4891 8.8 2.5 (2.4, 2.7)
Black
p=0.0025 Q1(Low) 247 1.9 1.0 (Ref)
Q2 198 2.6 1.3 (1.1, 1.6)
Q3 181 3.0 1.5 (1.3, 1.9)
Q4 147 3.4 1.8 (1.4, 2.2)
Q5(High) 117 4.5 2.3 (1.8, 2.9)
Asian
p=0.0199 Q1(Low) 84 2.4 1.0 (Ref)
Q2 248 4.9 2.1 (1.6, 2.7)
Q3 312 4.8 2.0 (1.6, 2.6)
Q4 478 5.5 2.3 (1.8, 3.0)
Q5(High) 716 6.6 2.8 (2.2, 3.5)
Gender
Male
p= 0.0014 Q1(Low) 318 1.1 1.0 (Ref)
Q2 491 1.7 1.4 (1.2, 1.7)
Q3 689 2.2 1.9 (1.7, 2.2)
Q4 888 2.7 2.4 (2.1, 2.7)
Q5(High) 1 266 3.7 3.2 (2.8, 3.7)
Female
p<0.0001 Q1(Low) 1 460 4.9 1.0 (Ref)
Q2 2 231 7.0 1.4 (1.3, 1.5)
Page 21 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 46
For peer review only
22
Q3 2 954 8.9 1.8 (1.7, 1.9)
Q4 3 685 10.7 2.2 (2.1, 2.3)
Q5(High) 4 557 12.8 2.6 (2.5, 2.8)
*SEER 18 excluding Alaska and Louisiana and cases with unknown SES.
†Fully Insured: Private Insurance; Fee-for-Service; Private Insurance: Managed care, HMO, or PPO; TRICARE; Medicare
Administered through a Managed Care plan; Medicare with private supplement; Medicare with supplement, NOS; and Military;
Other: Uninsured; Any Medicaid; Insured, No Specifics; and Insurance status unknown.
‡Age-adjusted rates adjusted to the 2000 US standard population.
Abbreviations: cm = centimeter; Q = quintile;; SEER = Surveillance, Epidemiology, and End Results; SES = census tract
socioeconomic status.
Page 22 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 47
For peer review only
Figure 1. Overall and age-specific thyroid cancer rate ratios by SES and insurance status for papillary thyroid cancers (PTC) and other histologies with stratification of PTCs <2 cm in size-- SEER registries, 2007-2010* *SEER 18 excluding Louisiana and Alaska cases and 283 cases with unspecified histologies (ICD-O-3 8000–
8005). 235x119mm (300 x 300 DPI)
Page 23 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 48
For peer review only
Figure 2. Gender- and race-specific thyroid cancer rate ratios by SES and insurance status for papillary thyroid cancers (PTC) and other histologies with stratification of PTCs <2 cm in size-- SEER registries, 2007-
2010* *SEER 18 excluding Louisiana and Alaska cases and 283 cases with unspecified histologies (ICD-O-3 8000–
8005). API: Asian/Pacific Islander 235x119mm (300 x 300 DPI)
Page 24 of 24
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960
on April 25, 2022 by guest. P
rotected by copyright.http://bm
jopen.bmj.com
/B
MJ O
pen: first published as 10.1136/bmjopen-2015-009843 on 7 D
ecember 2015. D
ownloaded from
Page 49
Manuscript ID bmjopen-2015-009843, entitled ‘Do US Thyroid Cancer Incidence Rates Increasewith Socioeconomic Status among People with Health Insurance?”STROBE Statement—checklist of items that should be included in reports of observational studies
ItemNo Recommendation
Title and abstract (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done
and what was found
Introduction
Background/rationale Explain the scientific background and rationale for the investigation being reported
Objectives State specific objectives, including any prespecified hypotheses
Methods
Study design f-i’resent key elements of study design early in the paper
Setting ‘‘escribe the setting, locations, and relevant dates, including periods of recruitment,
exposure, follow-up, and data collection
Participants —‘‘(a) Cohort study—Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of
case ascertainment and control selection. Give the rationale for the choice of cases
and controls
.__t’rosssectional study—Give the eligibility criteria, and the sources and methods of
selection of participants
(b) Cohort study—For matched studies, give matching criteria and number of
exposed and unexposed
Case-control study—For matched studies, give matching criteria and the number of
controls per case
Variables Clearly define all outcomes, exposures, predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable
Data Sources! For each variable of interest, give sources of data and details of methods of
measurement assessment (measurement). Describe comparability of assessment methods if there
7 is more than one group
Bias -, Describe any efforts to address potential sources of bias
Study size ‘IJY’ Explain how the study size was arrived at
Quantitative variables Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why
Statistical methods . (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was
addressed
Cross-sectional study—If applicable, describe analytical methods taking account of
sampling strategy
(e) Describe any sensitivity analyses
Continued on next page
on April 25, 2022 by guest. Protected by copyright.http://bmjopen.bmj.com/BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from
Page 50
-
22-”Give the source of funding and the role of the funders for the present study and, if applicable,
for the original study on which the present article is based
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and
unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com!). Information on the STROBE Initiative is
available at www.strobe-statement.org.
Results
Participants (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
analysed
(b) Give reasons for non-participation at each stage
cc) Consider use of a flow diagram
Descriptive 4,—’ia) Give characteristics of study participants (eg demographic, clinical, social) and information
data on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data l.57’Cohort study—Report numbers of outcome events or summary measures over time
Case-control study—Report numbers in each exposure category, or summary measures of
exposure
9ross-sectional study—Report numbers of outcome events or summary measures
Main results ,fr”(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
/time period
Other analyses U1’ Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
analyses
Discussion
Key results i,” unirnarise key results with reference to study objectives
Limitations j,9” Discuss limitations of the study, taking into account sources of potential bias or imprecision.
,Eiscuss both direction and magnitude of any potential bias
Interpretation Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
1of analyses, results from similar studies, and other relevant evidence
Generalisability 31” Discuss the generalisability (external validity) of the study results
Other information
Funding
2
on April 25, 2022 by guest. Protected by copyright.http://bmjopen.bmj.com/BMJ Open: first published as 10.1136/bmjopen-2015-009843 on 7 December 2015. Downloaded from